Belmont International

From the website:A great collection of creative, responsive, elegant onepage templates for different industries.

Whiston Asset Management is a Registered Investment Advisor, with 29 years of experience servicing the individual financial needs of investors. We are a fee based management firm focused on Asset Allocation. As a Financial and Insurance services company, we are better able to service the individual, and business needs of our global customers. We are Advisors who focus on knowing our customers and meet with each one individually. We are focused on giving you the client access to professional money management and investment choices needed to deliver the customized services to meet your investment objectives. We are a company that takes the time to understand each customer's long-term investment and insurance needs. We are in the business of offering long-term savings solutions and diversified retirement products. A company that can manage each clients risk tolerance by putting together customized products and services. We are a company who believes it is our job to stay current with market trends and economic changes and our obligation to know our customers. At Whiston Advisors, we use independent research, select the best managers, and use the latest technology. We follow a clear-cut, stream lined flexible structure for decision-making. Whiston Advisors is a company that is easy to do business with. We are a company that gives you access to your portfolio manager. A company that is accessible- anywhere, anytime, through a variety of channels, including toll free telephone, wireless texting, Internet, e-mail.

New Leaf Venture Partners' objectives with each investment are to back a strong, entrepreneurial management team, to provide appropriate financial resources, to help build a great company, and to create exceptional equity value. We are active investors and almost always serve as directors of our portfolio companies, who can draw upon perspectives and experiences of the entire NLV investment team and its network of successful scientists, clinicians, operating executives and entrepreneurs. We assist in building management teams, guiding corporate strategy, providing input to operating plans, and in making decisions about optimal paths for future financings and exits. As conditions evolve, NLV Partners team continually refines its differentiated strategy in healthcare investing. Both of NLV's latest funds, New Leaf Ventures I and New Leaf Ventures II, focus on taking leadership positions in: Biopharmaceuticals - NLV has an in-depth understanding of therapeutic targets and modalities, the drug R&D process, clinical trial design, regulatory requirements, and pharmaceutical commercial activities. NLV's extensive medical, clinical development, commercial and financial experience helps companies navigate the challenging path to regulatory approval and commercialization as stand-alone companies or through value-added strategic partnerships. NLV invests in companies at all stages in this sector, but looks at the level of risk, costs, and timelines to build real value in the underlying program (s) in determining if an investment fits our strategy. NLV has been particularly active in starting and investing in companies that been formed around the spin out of programs from larger pharmaceutical and biotech companies. Medical devices - NLV works closely with its network of entrepreneurs and scientific and medical founders to identify investment opportunities around promising technologies targeting areas of high unmet medical need and large commercial potential. The current strategy is to focus on later stage opportunities to provide growth capital or the last round to profitability in which regulatory and reimbursement risks are minimal. NLV will invest in early stage companies when there are large established global markets and an opportunity to prove safety and effectiveness in a focused, cost effective program. NLV's investment team brings critical operating experience and the ability to evaluate the biological, engineering, regulatory, reimbursement and market risks most relevant to starting, growing, developing and exiting young or more mature companies in the medical devices sector.